// OVERVIEW
Global pharmaceutical company acquiring cancer drug developer Nuvalent for $10.6B.
Discussed in
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
m_and_a·PitchBook News·JUNE 10, 2026
“GSK agreed to acquire Nuvalent, a developer of lung cancer treatments, for $10.6 billion.”
Source→02
m_and_a·Axios Pro Rata·JUNE 9, 2026
“GSK agreed to buy cancer drug developer Nuvalent for $10.6b in cash, or $124 per share (a 40% premium to yesterday's closing price).”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.